Basic information Safety Supplier Related

McN 5691

Basic information Safety Supplier Related

McN 5691 Basic information

Product Name:
McN 5691
Synonyms:
  • McN 5691
  • N-(3,4-Dimethoxyphenethyl)-5-methoxy-N,α-dimethyl-2-(phenylethynyl)benzenepropan-1-amine
  • N-[2-(3,4-Dimethoxyphenyl)ethyl]-5-methoxy-N,α-dimethyl-2-(phenylethynyl)benzenepropane-1-amine
  • RWJ-262240
  • RWJ-26240
  • N-[2-(3,4-dimethoxyphenyl)ethyl]-4-[5-methoxy-2-(2-phenylethynyl)phenyl]-N-methylbutan-2-amine
  • Benzenepropanamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-5-methoxy-N,α-dimethyl-2-(2-phenylethynyl)-
  • McN-5691,McN5691
CAS:
99254-95-2
MF:
C30H35NO3
MW:
457.61
Mol File:
99254-95-2.mol
More
Less

McN 5691 Chemical Properties

Boiling point:
595.6±50.0 °C(Predicted)
Density 
1.11±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
Soluble in DMSO
pka
9.22±0.50(Predicted)
More
Less

McN 5691 Usage And Synthesis

Uses

McN5691 is a voltage-sensitive calcium channel blocker.

in vivo

The excretion and metabolism of a 2-ethynylbenzenealkanamine analog, antihypertensive McN5691 (RWJ-26240), in beagle dogs is investigated. A total of 96.8% and 2.8% of the radioactive dose are excreted in feces and urine, respectively, during the 7 days after oral administration of 14C-McN5691. Of the radioactive dose, 96.8% and 2.8% is recovered in feces and urine, respectively, in the 7 days after oral administration of 14C-McN5691. More than 87% of the dose is excreted in feces during the 48 hours. McN5691 is extensively metabolized in dogs. Unchanged McN5691 is found in less than 0.1% and 19% of the dose in the 0-24 hour urine and 0-48 hour fecal extract, respectively, and 36% of the sample in the 4 hour plasma[2]. In the McN5691 (McN-5691) study, vascular resistances tend to be higher in spontaneously hypertensive rat (SHR) than in Wistar-Kyoto (WKY) but the differences are statistically significant only in the cerebellum and the midbrain[3].

References

[1] Flaim SF, et al. Structurally novel antihypertensive compound, McN-5691, is a calcium channel blocker in vascular smooth muscle. J Pharmacol Exp Ther. 1991 Jan;256(1):279-88. PMID:1846419
[2] Wu WN, et al. Excretion and metabolism of the antihypertensive agent, RWJ-26240 (McN-5691) in dogs. Drug Metab Dispos. 1998 Feb;26(2):115-25. PMID:9456297
[3] Flaim SF, et al. Effects of the novel calcium channel blocker, McN-5691, on cardiocirculatory dynamics and cardiac output distribution in conscious spontaneously hypertensive rat. J Cardiovasc Pharmacol. 1988 Apr;11(4):489-500. DOI:10.1097/00005344-198804000-00017

McN 5691Supplier

MedChemexpress LLC
Tel
021-58955995
Email
sales@medchemexpress.cn
Fan De(Beijing) Biotechnology Co., Ltd.
Tel
15911056312
Email
liming@bio-fount.com
TargetMol Chemicals Inc.
Tel
+1-781-999-5354; +17819995354
Email
marketing@targetmol.com
cjbscvictory
Tel
13348960310
Email
3003867561@qq.com
Beijing Jin Ming Biotechnology Co., Ltd.
Tel
010-60605840 15801484223;
Email
psaitong@jm-bio.com